首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer journal

缩写:CANCER J

ISSN:1528-9117

e-ISSN:1540-336X

IF/分区:2.1/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引1187条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Ravi A Madan,James L Gulley,Philip W Kantoff Ravi A Madan
Immunotherapy has emerged as a viable therapeutic option for patients with prostate cancer. There are multiple potential strategies that use the immune system, including therapeutic cancer vaccines that are designed to stimulate immune cell...
Dana Rathkopf,Howard I Scher Dana Rathkopf
Persistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC). As proof of principle that the AR remains relevant...
Roberta Ferraldeschi,Johann de Bono Roberta Ferraldeschi
In April 2011, abiraterone acetate (in combination with low-dose steroids) was approved by the US Food and Drug Administration for the treatment of men with metastatic, castration-resistant prostate cancer who have previously been treated w...
Rhonda L Bitting,Andrew J Armstrong Rhonda L Bitting
With the surge in therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specifi...
Ajjai Alva,Maha Hussain Ajjai Alva
Since 1941, the understanding of prostate cancer pathogenesis and therapy has undergone a significant transformation. Rigorous translational research has identified multiple mechanisms underlying castration resistance, the fatal clinical st...
Soley Bayraktar,Angelica M Gutierrez Barrera,Diane Liu et al. Soley Bayraktar et al.
Purpose: USP-11, a member of the ubiquitin-specific protease family, has emerged as an essential regulator of double-strand break repair. Few studies have shown that silencing USP-11 led to hypersensitivity to poly(ADP-ri...
Justin P Fox,Diana D Jeffery,Thomas V Williams et al. Justin P Fox et al.
Purpose: Following the acute phase of treatment, national guidelines recommend cancer survivors have routine contact with health care providers and undergo basic ancillary testing while avoiding high-cost imaging (HCI). W...
Renee Tholey,Janet A Sawicki,Jonathan R Brody Renee Tholey
The current treatment options for pancreatic ductal adenocarcinoma fall exceedingly short of a cure, providing a sobering 5-year survival rate of only 5% for all patients, and the disease will be responsible for more than 37,000 deaths in t...
Pelin Cinar,Margaret A Tempero Pelin Cinar
Pancreatic cancer continues to be a challenging disease to treat because of its aggressive nature, advanced stage at the time of diagnosis, and limited treatment options that are available. Traditional cytotoxic chemotherapy provides modest...